Novartis bids final farewell to HCV with Debiopharm
Novartis has completed its exit from the hepatitis C arena and given back the
rights to alisporivir to fellow Swiss firm Debiopharm.
Debiopharm said it
has regained full rights to alisporivir which is currently completing two Phase
II studies as part of interferon-free treatment in HCV. The company believes the
compound, a non-immunosuppressive cyclophilin inhibitor, has the potential to be
used for other viral infections, certain muscular dystrophies, and myocardial
infarction
Read more
Alisporivir program rights returned to Debiopharm
Debiopharm Group has regained all rights to Alisporivir, a cyclophilin inhibitor being investigated for the treatment of hepatitis C virus infection, as a result of a new agreement between the pharmaceutical company and Novartis, according to a news release from the company.
No comments:
Post a Comment